Quentin Clemens, MD

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)
    Ineligible company: 
    Lundbeck
    Mitigation strategy: 
    Peer review
    Relationship end date: 
    09/15/2021
    Date reviewed: 
    09/09/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)
    Ineligible company: 
    Bayer
    Mitigation strategy: 
    Peer review
    Relationship end date: 
    11/12/2021
    Date reviewed: 
    09/09/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)
    Ineligible company: 
    Glaxo Smith Kline
    Mitigation strategy: 
    Peer review
    Relationship end date: 
    12/31/2021
    Date reviewed: 
    09/09/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)
    Ineligible company: 
    UroCure
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/09/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Investment Interest (General Urology)
    Ineligible company: 
    Merck
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/09/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)
    Ineligible company: 
    Atellas
    Mitigation strategy: 
    Peer review
    Relationship end date: 
    03/01/2021
    Date reviewed: 
    09/09/2022
Return to Update Series (2022) Lesson 25: New Developments in Interstitial Cystitis/Bladder Pain Syndrome